文献速递垂体与肾上腺疾病性腺与生殖内分泌

46,XX患者POR基因R550W突变所致CYP19A1缺陷的分子基础:扩展PORD表型

Molecular Basis of CYP19A1 Deficiency in a 46,XX Patient With R550W Mutation in POR: Expanding the PORD Phenotype.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

报告一例46,XX患者携带POR基因R550W突变,表现为芳香化酶缺乏体征;重组蛋白实验显示POR-R550W对细胞色素c活性为野生型的41%,对MTT还原活性为7.7%,CYP19A1活性严重丧失,CYP17A1和CYP21A2活性丧失超过95%。结论认为POR-R550W的病理效应扩展了芳香化酶缺乏相关分子通路认识,筛查POR基因可能为类固醇代谢酶基因无缺陷的先天性肾上腺增生提供诊断。

要点

  • 46,XX患者携带POR复合杂合突变c.73_74delCT/p.L25FfsTer93和c.1648C>T/p.R550W,表现芳香化酶缺乏体征。
  • POR-R550W对细胞色素c活性为野生型的41%,对MTT还原活性为7.7%。
  • CYP19A1活性严重丧失,CYP17A1和CYP21A2活性丧失超过95%。

核心结论

  • POR-R550W的病理效应被确认,扩展了芳香化酶缺乏相关分子通路的知识。
  • 筛查POR基因可能为类固醇代谢酶基因无缺陷的先天性肾上腺增生提供诊断。

研究设计与样本

  • 病例报告:一例46,XX患者及其母亲有男性化体征,超声显示子宫和卵巢。
  • 采用靶向性发育障碍NGS面板(DSDSeq.V1,111个基因)在NextSeq(Illumina)平台检测,地点为西班牙马德里和巴塞罗那。
  • 将野生型和R550W POR作为重组蛋白生产,在瑞士伯尔尼大学儿童医院用多种细胞色素P450酶进行测试。

主要发现

  • POR-R550W对细胞色素c活性为野生型的41%,对MTT还原活性为7.7%。
  • CYP19A1活性严重丧失,CYP17A1和CYP21A2活性丧失超过95%。
  • 观察到R550W-POR的CYP2C9、CYP2C19和CYP3A4活性丧失。
  • 预测的对芳香化酶活性的不良影响以及NADPH结合减少被证实。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Mutations in cytochrome P450 oxidoreductase (POR) cause a form of congenital adrenal hyperplasia (CAH). We report a novel R550W mutation in POR identified in a 46,XX patient with signs of aromatase deficiency. OBJECTIVE: Analysis of aromatase deficiency from the R550W mutation in POR. DESIGN, SETTING, AND PATIENT: Both the child and the mother had signs of virilization. Ultrasound revealed the presence of uterus and ovaries. No defects in CYP19A1 were found, but further analysis with a targeted Disorders of Sexual Development NGS panel (DSDSeq.V1, 111 genes) on a NextSeq (Illumina) platform in Madrid and Barcelona, Spain, revealed compound heterozygous mutations c.73_74delCT/p.L25FfsTer93 and c.1648C > T/p.R550W in POR. Wild-type and R550W POR were produced as recombinant proteins and tested with multiple cytochrome P450 enzymes at University Children's Hospital, Bern, Switzerland. MAIN OUTCOME MEASURE AND RESULTS: POR-R550W showed 41% of the WT activity in cytochrome c and 7.7% activity for reduction of MTT. Assays of CYP19A1 showed a severe loss of activity, and CYP17A1 as well as CYP21A2 activities were also lost by more than 95%. Loss of CYP2C9, CYP2C19, and CYP3A4 activities was observed for the R550W-POR. Predicted adverse effect on aromatase activity as well as a reduction in binding of NADPH was confirmed. CONCLUSIONS: Pathological effects due to POR-R550W were identified, expanding the knowledge of molecular pathways associated with aromatase deficiency. Screening of the POR gene may provide a diagnosis in CAH without defects in genes for steroid metabolizing enzymes.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Parween S, Fernández-Cancio M, Benito-Sanz S, et al. Molecular Basis of CYP19A1 Deficiency in a 46,XX Patient With R550W Mutation in POR: Expanding the PORD Phenotype. J Clin Endocrinol Metab. 2020. PMID: 32060549. doi:10.1210/clinem/dgaa076

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。